Fig. 3: TYRP1 CAR with a long flexible hinge exhibits superior tumor control in TYRP1high syngeneic and patient-derived melanoma models.
a, d, g, j, l Schematics of the in vivo mouse studies indicating the timeline, tumor cell and CAR-T cell doses, and irradiation and IL-2 doses and timelines if applicable. Graphical depictions were created with BioRender.com. b, e, h, k, m Kinetic of tumor growth or regression over time after treatment with 20D7S-derived CAR-T cells alone or in combination with IL-2. Untransduced T cells or CD19 CAR-T cells and vehicle were used as controls. Mean ± SEM are plotted (b: n = 8, e: n = 10, h: n = 10 for 20D7SL and 20D7SL + IL2, n = 6 for UTD, n = 5 for UTD + IL2, n = 9 for PBS, k: n = 10, m: n = 10). * p < 0.05, ** p < 0.005, **** p < 0.0005 unpaired, two-tailed t test with Holm-Sidak adjustment for multiple comparisons. c, f, i Kaplan-Meier survival curves. Survival differences are statistically significant. Log-rank (Mantel-Cox) p < 0.0001. n Percentage of CD3+ cells from single cells in B16 tumors treated with 20D7SL-28z or untransduced CAR-T cells on Day 13 after ACT. Mean ± SEM is plotted (n = 4 for UTD, n = 3 for 20D7SL-28z). Percentage of CD45+ from single cells in tumors (o) and spleens (p) of M207-bearing mice treated with 20D7SL-28z or untransduced CAR-T cells at day 5, 11, and 21 after ACT. Mean ± SEM are plotted (in (o), n = 2 for UTD day 5, n = 1 for UTD days 11 and 21, n = 3 for 20D7SL-28z day 5 and n = 4 for 20D7SL-28z days 11 and 21. In (p), n = 1 for UTD and n = 2 for 20D7SL-28z at all time points). Source data and exact p values are provided as a Source Data file.
